Latest osteosarcoma Stories
Epeius Biotechnologies has announced that Rexin-G has received orphan drug designation from the FDA for the treatment of osteosarcoma.
SAN MARINO, Calif., July 8 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.
By Daniel Axelrod, The Times-Tribune, Scranton, Pa. Jul. 6--TOBYHANNA -- Fifteen-year-old Alexandria "Xandi" Robbins' 5-foot-7-inch frame dropped from 300 to 125 pounds in the 16 months before she died in September at her Tobyhanna home.
By Frattini, Jared C Sosa, Julie Ann; Carmack, Susanne; Robert, Marie E * Data from the nuclear reactor explosion in Chernobyl and the atomic bomb detonations in Hiroshima and Nagasaki demonstrated an association between ionizing radiation and tumoriogenesis.
By David Douglas NEW YORK (Reuters Health) - Hearing loss appears to be a significant and under-reported side effect of platinum-based drugs used to treat a variety of childhood cancers, according to researchers. As senior investigator Dr. Edward A.
By Will Boggs, MD NEW YORK (Reuters Health) - Hearing loss may be more common than previously reported in children with cancer who have undergone chemotherapy with highly effective platinum-type drugs such as cisplatin and carboplatin, researchers report.
Although as many as 70 percent of patients who have the localized stage of the bone cancer osteosarcoma survive after surgery and chemotherapy, the overall survival rate after recurrence is less than 30 percent, researchers report.
Stem cells may cause some forms of bone cancer, University of Florida scientists report.
Core-needle biopsy guided by CT scans or ultrasound appears to be an effective way to obtain tumor samples diagnosis of pediatric solid tumors, say St. Jude Childrenâ€™s Research Hospital researchers.
- The parings of haberdine; also, any kind of fragments.